Finoriq research workspace
ARVINAS, INC. (ARVN) SEC Filings & Filing Highlights
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development. Review ARVN SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
- Company
- ARVINAS, INC. (ARVN)
- Ticker
- ARVN
- Market Cap
- $516.5M
- Latest Price
- $8.005
- Industry
- Biotech & Pharma
ARVINAS, INC. (ARVN) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for ARVINAS, INC. (ARVN).
| Event | Form | Date |
|---|---|---|
| 1. Proposal No. 1 - Election of Two Class II DirectorsOn June 24, 2026, Arvinas, Inc. (the "Company") held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote upon th... | 8-K5.07 | 2026-06-25 |
| On June 22, 2026, Arvinas, Inc., a Delaware corporation (the “Company”), and Noah Berkowitz, M....On June 22, 2026, Arvinas, Inc., a Delaware corporation (the “Company”), and Noah Berkowitz, M.D., Ph.D., the Company’s chief medical offic... | 8-K5.02 | 2026-06-22 |
| Date: June 16, 2026As previously announced, on May 11, 2026, Arvinas, Inc., a Delaware corporation (“Arvinas”), and Arvinas’ direct subsidiaries, Arvinas Oper... | 8-K8.01 | 2026-06-16 |
| exhibit991-presentationjARVINAS, INC. filed a Form 8-K covering corporate update | 8-K8.01 | 2026-06-02 |
| exhibit991-presentationjexhibit991-presentationj | 8-K7.01 | 2026-06-02 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.